. 2021 Apr 4;36(11):2399–2410. doi: 10.1007/s00384-021-03914-w

Table 2.

Cumulative incidence of recurrence and hazards for recurrence among patients with right-sided colon cancer

	Stage I–II (N = 1195)	Stage III (N = 612)
Gender
Male Female	0.10 0.07	1.00 (reference) 0.56 (0.36–0.86)	0.30 0.32	1.00 (reference) 1.05 (0.78–1.41)
Age
<65 years 65–74 years ≥75 years	0.06 0.09 0.10	1.00 (reference) 2.00 (1.07–3.72) 1.75 (0.93–3.28)	0.25 0.32 0.35	1.00 (reference) 1.14 (0.77–1.68) 0.88 (0.55–1.42)
ASA classification
ASA I ASA II ASA III ASA IV	0.08 0.09 0.10 n.r.	1.00 (reference) 0.82 (0.43–1.58) 0.80 (0.39–1.61) n.r.	0.19 0.29 0.39 n.r.	1.00 (reference) 1.56 (0.94–2.61) 1.85 (1.05–3.26) n.r.
pT stage
1 2 3 4	0.03 0.03 0.09 0.31	0.41 (0.16–1.04) 0.32 (0.15–0.69) 1.00 (reference) 4.84 (2.88–8.12)	n.r. 0.15 0.27 0.48	n.r. 0.55 (0.27–1.14) 1.00 (reference) 1.90 (1.39–2.59)
pN stage
0 1 2	0.09 n.a. n.a.	1.00 (reference) n.a. n.a.	n.a. 0.24 0.45	n.a. 1.00 (reference) 2.03 (1.49–2.76)
Morphology
Adenocarcinoma Mucinous adenocarcinoma Signet ring cell carcinoma	0.09 0.03 n.r.	1.00 (reference) 0.51 (0.15–1.69) n.r.	0.30 0.32 0.56	1.00 (reference) 1.04 (0.60–1.80) 1.37 (0.54–3.49)
Differentiation grade
Well/moderate Poor/undifferentiated	0.08 0.16	1.00 (reference) 2.14 (1.22–3.76)	0.26 0.43	1.00 (reference) 1.83 (1.26–2.65)
Microsatellite status
Stable Instable	0.12 0.04	1.00 (reference) 0.31 (0.07–1.45)	0.36 0.19	1.00 (reference) 0.42 (0.19–0.91)
Treatment
Surgery Surgery + adjuvant chemotherapy~	0.08 0.15	Not included	0.37 0.28	1.00 (reference) 0.61 (0.41–0.93)

Stage I–II (N = 1195)

Stage III (N = 612)

Crude 3-year cumulative incidence

Adjusted HR*
(95% CI)

Crude 3-year cumulative incidence

Adjusted HR*
(95% CI)

Gender

Male

Female

0.10

0.07

1.00 (reference)

0.56 (0.36–0.86)

0.30

0.32

1.00 (reference)

1.05 (0.78–1.41)

Age

<65 years

65–74 years

≥75 years

0.06

0.09

0.10

1.00 (reference)

2.00 (1.07–3.72)

1.75 (0.93–3.28)

0.25

0.32

0.35

1.00 (reference)

1.14 (0.77–1.68)

0.88 (0.55–1.42)

ASA classification

ASA I

ASA II

ASA III

ASA IV

0.08

0.09

0.10

n.r.

1.00 (reference)

0.82 (0.43–1.58)

0.80 (0.39–1.61)

n.r.

0.19

0.29

0.39

n.r.

1.00 (reference)

1.56 (0.94–2.61)

1.85 (1.05–3.26)

n.r.

pT stage

0.03

0.09

0.31

0.41 (0.16–1.04)

0.32 (0.15–0.69)

1.00 (reference)

4.84 (2.88–8.12)

n.r.

0.15

0.27

0.48

n.r.

0.55 (0.27–1.14)

1.00 (reference)

1.90 (1.39–2.59)

pN stage

0.09

n.a.

1.00 (reference)

n.a.

0.24

0.45

n.a.

1.00 (reference)

2.03 (1.49–2.76)

Morphology

Adenocarcinoma

Mucinous adenocarcinoma

Signet ring cell carcinoma

0.09

0.03

n.r.

1.00 (reference)

0.51 (0.15–1.69)

n.r.

0.30

0.32

0.56

1.00 (reference)

1.04 (0.60–1.80)

1.37 (0.54–3.49)

Differentiation grade

Well/moderate

Poor/undifferentiated

0.08

0.16

1.00 (reference)

2.14 (1.22–3.76)

0.26

0.43

1.00 (reference)

1.83 (1.26–2.65)

Microsatellite status

Stable

Instable

0.12

0.04

1.00 (reference)

0.31 (0.07–1.45)

0.36

0.19

1.00 (reference)

0.42 (0.19–0.91)

Treatment

Surgery

Surgery + adjuvant chemotherapy~

0.08

0.15

Not included

0.37

0.28

1.00 (reference)

0.61 (0.41–0.93)

ASA classification unknown, T stage unknown, N stage unknown, other morphology, unknown differentiation grade, and unknown microsatellite status were included in the analyses but results not shown

HR, hazard ratio; CI, confidence interval; n.a., not applicable; n.r., not reported, numbers too small

To prevent problems with multicollinearity between pT, pN, and TNM stage in the multivariable model, TNM stage is not included in the multivariable model

*Competing risk analysis for death as competing event that prevents CRC recurrence from occurring. Hazard ratios are cause-specific hazards for recurrence in the presence of the competing risk of dying

~ In the Netherlands, adjuvant chemotherapy is only recommended for patients with stage III or high-risk stage II colon cancer and not routinely given to rectal cancer patients